TargetBeta
ADRA2B
adrenoceptor alpha 2B · also ADRARL1, ADRA2L1, ADRA2RL1 · Adrenoceptors
8 programs in company-led studies act on ADRA2B, from 7 companies: 1 in phase 3, 7 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (8 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Epinephrinerule | Nasus Pharma | phase 4 | 175 running | ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2C, ADRB1, ADRB2, ADRB3 | ChEMBL |
| Dexmedetomidinerule | Pfizer | phase 4 | 463 running | ADRA2A, ADRA2C | ChEMBL |
| brimonidinerule | AbbVie | phase 4 | 542 running | ADRA2A, ADRA2C | ChEMBL |
| Oxymetazolinerule | AbbVie | phase 4 | 201 running | ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2C | ChEMBL |
| Phentolaminerule | Opus Genetics | phase 4 | 181 running | ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2C | ChEMBL |
| tizanidinerule | Teva Pharmaceutical Industries | phase 4 | 111 running | ADRA2A, ADRA2C | ChEMBL |
| Clonidinerule | PHARMAFINA | phase 4 | 50 running | ADRA2A, ADRA2C | ChEMBL |
| lofexidinerule | USWM, LLC (dba US WorldMeds) | phase 3 | 150 running | ADRA2A, ADRA2C | ChEMBL |
Conditions their studies are in
- Glaucoma, Open-Angle, 2 programs
- Rosacea, 2 programs
- Anaphylaxis, 1 program
- Asthma, 1 program
- Attention Deficit Disorder with Hyperactivity, 1 program
- Bipolar Disorder, 1 program
- Cerebral Palsy, 1 program
- Chronic Urticaria, 1 program
- Cognitive Dysfunction, 1 program
- Conjunctivitis, Allergic, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Apr 2027Epinephrine · Nasus Pharma · phase 4 · NCT06834165
- Jul 15, 2027tizanidine · Teva Pharmaceutical Industries · phase 4 · NCT07932613
- Jul 31, 2027Dexmedetomidine · Pfizer · phase 4 · NCT05025605
- Aug 2027Phentolamine · Opus Genetics · phase 4 · NCT07140783
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.